ライフサイエンスコーパス: virologic

1 (pLLV) and quantified the risk of subsequent virologic.

2 xperienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.

3 ller phenotype and performed immunologic and virologic analysis of blood, lymph node, and colorectal

4 Virologic analysis revealed the emergence of multiple in

5 computed tomography and histopathologic and virologic analysis, was performed.

6 the Working Group's review of the available virologic and clinical literature and will be subject to

7 ivariate models were constructed to identify virologic and clinical variables predictive of clinical

8 ing for preexisting immunity when evaluating virologic and immunologic responses to LAIVs.

9 n study design, patient characteristics, and virologic and safety outcomes sequentially and assessed

10 ween fibrosis progression and epidemiologic, virologic, and disease-associated factors were analyzed

11 We compared their clinical, virologic, and immunologic features vs 20 patients with

12 t particularly in children with SVS, without virologic blips, that was achieved with the first cART r

13 nts were categorized into mutually exclusive virologic categories: intermittent LLV (iLLV) (VL of 50-

14 Assessments included virologic characteristics and relationship with CMV, ris

15 We describe the clinical and virologic characteristics of 5 children admitted with ad

16 The clinical and virologic characteristics of Ebola virus disease (EVD) i

17 Clinical and virologic characterization of these samples is reported

18 chloroquine found minor fever resolution and virologic clearance benefits with chloroquine.

19 Coincident virologic clearance was confirmed by in situ hybridizati

20 se, clinical symptoms, and upper respiratory virologic clearance with antigen testing.

21 ke protein (S protein) associated with rapid virologic clearance.

22 ss (ARI), defined by specified symptoms with virologic confirmation.

23 ersistent LLV is associated with deleterious virologic consequences.

24 roughout 48 weeks of combination therapy and virologic control (HBsAg positive, HBV DNA below 2000 IU

25 body against alpha(4)beta(7) induced durable virologic control after ART discontinuation in 100% of r

26 cted CD4 T cells in individuals with natural virologic control by sequencing viruses, T cell receptor

27 the published report, we found no sustained virologic control by these treatments in vivo.

28 g on ritonavir-boosted lopinavir (LPV/r) for virologic control in children infected with human immuno

29 radicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral thera

30 e to seasonal influenza vaccination, despite virologic control of HIV.

31 Sustained virologic control of human immunodeficiency virus type 1

32 ed with COVID-19 had high proportions of HIV virologic control on antiretroviral therapy.

33 During 48 weeks of treatment-free follow-up, virologic control persisted in 13 of 40 participants (2

34 s is low, suggesting efficient mechanisms of virologic control within the CNS.

35 f HBV therapeutics to achieve functional and virologic cure in various phases of HBV infection.

36 stay, need for mechanical ventilation (MV), virologic cure rate (VQR), time to a negative viral poly

37 Clinical and virologic data were collected.

38 potentially important new insights into the virologic determinants of early CMV infection.

39 oring is required to realize the benefits of virologic determination of cART failure.

40 Participating physicians reported clinical, virologic diagnosis, and outcome variables using a stand

41 T program is a feasible model with excellent virologic effectiveness.

42 Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque mo

43 g) or placebo and evaluated the quantitative virologic end points and clinical outcomes.

44 efore, either new ways of using the existing virologic endpoints and laboratory values or entirely ne

45 ng among ART experienced Ugandan adults with virologic failure (>=1,000 copies/mL) using leftover pla

46 ng among ART-experienced Ugandan adults with virologic failure (>=1000 copies/mL) using leftover plas

47 virologic suppression (88%-93%), subsequent virologic failure (0.1%-0.6%/month), and Medicaid-discou

48 Virologic failure (a viral load of >1000 copies per mill

49 of post-ART follow-up, 19 (24%) experienced virologic failure (dapivirine: 6/32, 19%; placebo: 13/39

50 200 copies/mL doubled the risk of developing virologic failure (pLLV 200-499: HR, 1.81 [95% CI, 1.08-

51 persistent low-level viremia (pLLV) predicts virologic failure (VF) is unclear.

52 Virologic failure (VF) was defined as 2 consecutive HIV

53 sent in 817 (56.5%) of 1445 individuals with virologic failure (VF).

54 fected with hepatitis C virus who experience virologic failure after treatment with direct-acting ant

55 Participants with virologic failure and anticipated antiretroviral suscept

56 Identification of virologic failure and early management mitigates the gre

57 No patients had virologic failure during treatment, and no patients had

58 HIV-1 disease progression and virologic failure following initiation of ART were asses

59 confirmed nonadherence as the major cause of virologic failure for 9 (45%) of 20 highly treatment-exp

60 prescribed ART for at least 6 months without virologic failure for pLLV.

61 RNA levels from 330 subjects who experienced virologic failure in clinical trials of direct-acting an

62 (1%) and was only associated with increased virologic failure in patients treated for short duration

63 Ag screening is cost-effective in those with virologic failure is unknown.

64 high rates of sustained virologic response, virologic failure may still occur, potentially leading t

65 Virologic failure occurred in 13 (33%) of 39 and relapse

66 Virologic failure occurred in no patients in arm A and i

67 xposure to both NRTI and NNRTI and confirmed virologic failure on a PI-containing regimen were requir

68 hibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor-containing reg

69 n vs a TAF-based regimen at week 48, with no virologic failure or emergent resistance reported with D

70 No virologic failure or significant NC changes were detecte

71 No virologic failure or significant NC changes were detecte

72 countries (LMICs) experience higher rates of virologic failure than adults.

73 HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy.

74 Virologic failure was defined as 2 consecutive human imm

75 Virologic failure was uncommon after week 48.

76 Among 1186 subjects with virologic failure, 35 (3.0%) were CrAg positive with med

77 Among 1,186 subjects with virologic failure, 35 (3.0%) were CrAg-positive with med

78 ew DM diagnosis plus DM-related medication), virologic failure, cART regimen switch, administrative c

79 or >=1 year in 2005-2015 were followed until virologic failure, loss to follow-up, death, or study en

80 he outcome of treatment-which contributes to virologic failure, resistance generation and viral trans

81 s were found in 20 of 47 patients (43%) with virologic failure.

82 pies/mL were at increased risk of subsequent virologic failure.

83 times to virologic suppression and risks of virologic failure.

84 ion of antiretroviral therapy and to prevent virologic failure.

85 l, Mozambique, were previously evaluated for virologic failure.

86 No patient had virologic failure.

87 pleted treatment in either study experienced virologic failure.

88 .15; 95% CI, 1.03-1.28) were associated with virologic failure.

89 in a subset of patients treated with SOF at virologic failure.

90 reappeared at relapse in all 3 patients with virologic failure.

91 ications were associated with higher odds of virologic failure.

92 Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 mo

93 ith the detection of R155K/D168A in NS3 from virologic failures treated with simeprevir but not grazo

94 There were no protocol-defined virologic failures; incidences of adverse events (AEs) a

95 There were no protocol-defined virologic failures; incidences of adverse events (AEs) a

96 We characterized immunologic and virologic features associated with post-ART SIV control

97 We describe the clinical and virologic features of URIs that remain uncomplicated and

98 The clinical, serologic, and virologic features were compared between the 2 groups.

99 of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages.

100 United States influenza virologic, hospitalization, and mortality surveillance d

101 We performed virologic, immunological, and pathogenic characterizatio

102 rruption (ATI); however, the immunologic and virologic impact of ATI in individuals who initiated ART

103 without oseltamivir) resulted in significant virologic improvements over placebo, demonstrated trends

104 meters including a prior vaccination status, virologic measures, and clinical variables.

105 and the virus cannot be studied by classical virologic methods because it cannot be readily isolated

106 iding robust adherence support, and ensuring virologic monitoring for children receiving ART are esse

107 Improved implementation of virologic monitoring is required to realize the benefits

108 viral therapy (ART) regimens with infrequent virologic monitoring.

109 e after initiation of ART heralded a lack of virologic or clinical response, and hence their monitori

110 Virologic or complete cure additionally includes loss of

111 njections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline.

112 he impact of low-frequency RPV resistance on virologic outcome during subsequent antiretroviral thera

113 hs, which resulted in better immunologic and virologic outcomes compared to those who did not switch

114 antiretrovirals in hair are associated with virologic outcomes in cohorts of human immunodeficiency

115 Risk factors, virologic parameters and outcomes associated with HHV-6

116 Radiographic (mean 6 +/- 5 days) and virologic recovery (mean 8 +/- 6 days) were not signific

117 SVR12 after 8 weeks of treatment experienced virologic relapse after stopping therapy.

118 lure during treatment, and no patients had a virologic relapse after the end of treatment.

119 retreatment, it is important to distinguish virologic relapse from reinfection when patients in whom

120 nalysis of multiple HCV genes to distinguish virologic relapse from reinfection.

121 Distinguishing reinfection from virologic relapse has implications for determining true

122 g 5 patients with late recurrent viremia had virologic relapse in which the HCV present at baseline p

123 Neither virologic relapses nor serious adverse events were noted

124 erapeutic strategies for achieving sustained virologic remission are being explored in human immunode

125 he use of ATI to determine whether sustained virologic remission has been achieved in clinical trials

126 entions may be necessary to achieve ART-free virologic remission.

127 ey represent alternate pathways to baloxavir virologic resistance and should be monitored accordingly

128 47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI, 0.55-2.3

129 The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitat

130 Primary endpoint was virologic response (HIV-1 RNA <50 copies/mL; intent-to-t

131 Primary endpoint was virologic response (HIV-1 RNA <50 copies/mL; intent-to-t

132 At week 48, a virologic response (HIV-1 RNA level, <40 copies per mill

133 but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).

134 of 12 weeks of therapy; all had a sustained virologic response (no detectable serum HCV RNA 12 weeks

135 T]; >3 mo-2 years, late therapy [LT]) and by virologic response (R) or non-response (NR), before and

136 Those who achieved sustained virologic response (SVR) (n = 141; 94%) were eligible fo

137 If this cohort had a 90% rate of sustained virologic response (SVR) 4 weeks after treatment, a seco

138 (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment wit

139 Sustained virologic response (SVR) after direct acting antiviral a

140 95% CI 12.2-14.5) for those with a sustained virologic response (SVR) and 19.2 (95% CI 17.4-21.1) for

141 iated with increased likelihood of sustained virologic response (SVR) and an association between achi

142 Rates of sustained virologic response (SVR) at 12 weeks were available on 4

143 Pre-treatment predictors of sustained virologic response (SVR) at 24 weeks following discontin

144 d continued HCC surveillance after sustained virologic response (SVR) has been achieved.

145 f care for promoting adherence and sustained virologic response (SVR) have not been evaluated in the

146 m 2000 through 2015 and achieved a sustained virologic response (SVR) in the Veterans Health Administ

147 Multivariate models of sustained virologic response (SVR) included age, race, cirrhosis,

148 ane Group remains unconvinced that sustained virologic response (SVR) is a validated surrogate outcom

149 nodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.

150 to the study-defined, historical, sustained virologic response (SVR) of 60% with pegylated-interfero

151 The impact of sustained virologic response (SVR) on mortality after direct-actin

152 Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patients with H

153 High sustained virologic response (SVR) rates have been observed after

154 Long-term changes after sustained virologic response (SVR) remain unknown.

155 Sustained virologic response (SVR) to interferon (IFN)-free therap

156 ere associated with lower rates of sustained virologic response (SVR) to interferon-based treatments

157 48 patients who completed therapy, sustained virologic response (SVR) was achieved in 43 (89.6%).

158 Sustained virologic response (SVR) was not achieved in 9 participa

159 l [CI], .33-.57) and attainment of sustained virologic response (SVR) were associated with significan

160 treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR.

161 The primary end point was sustained virologic response (SVR), and secondary end points inclu

162 arch 2018) was conducted to assess sustained virologic response (SVR), discontinuation rates, adheren

163 are associated with high rates of sustained virologic response (SVR), generally exceeding 90%.

164 were minimal and did not differ by sustained virologic response (SVR), HIV, diabetes, or fibrosis.

165 erapies are effective in achieving sustained virologic response (SVR), however, whether successful DA

166 ahepatic benefits of a DAA-induced sustained virologic response (SVR).

167 ing antiviral (DAA) treatment, and sustained virologic response (SVR).

168 tained pre-HCV treatment and after sustained virologic response (SVR).

169 h DAA, and 29,090 (19.4%) achieved sustained virologic response (SVR).

170 t, and 119 (91% of initiators) had sustained virologic response (SVR).

171 of the host response could predict sustained virologic response (SVR).

172 greater risk of reinfection after sustained virologic response (SVR).

173 s is associated with high rates of sustained virologic response (SVR).

174 als, and 29 090 (19.4%) achieved a sustained virologic response (SVR).

175 therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sof

176 Key outcomes included sustained virologic response (undetectable HCV RNA 12 weeks after

177 Primary endpoint was sustained virologic response 12 weeks after end of treatment (12 w

178 achieved the primary outcome of a sustained virologic response 12 weeks after the date of the last d

179 e recurrent viremia (patients with sustained virologic response 12 weeks after the end of treatment b

180 The primary end point was a sustained virologic response 12 weeks after the end of treatment.

181 s had detectable HCV RNA following sustained virologic response 12 weeks after the end of treatment.

182 Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment.

183 whether patients who maintained a sustained virologic response 12 weeks after therapy (SVR12) with d

184 The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12).

185 the percentage of patients with a sustained virologic response 12 weeks after treatment (SVR12).

186 The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12).

187 class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12).

188 The primary end point was sustained virologic response 12 weeks after treatment (SVR12).

189 avirin, demonstrated high rates of sustained virologic response 12 weeks after treatment ended (SVR12

190 weeks treatment with G/P produced sustained virologic response 12 weeks after treatment in >90% of p

191 Proportions of patients with sustained virologic response 12 weeks after treatment in groups A,

192 The primary end point was a sustained virologic response 12 weeks after treatment.

193 HCV RNA positive, 345 treated with sustained virologic response [SVR], 43 during treatment, and 281 t

194 ronic HCV infection who achieved a sustained virologic response after 12 weeks of treatment with sofo

195 ks in patients who did not achieve sustained virologic response after prior treatment with direct-act

196 HCV-RNA in the explant achieved a sustained virologic response after receiving their liver transplan

197 cted individuals can achieve a sustained HCV virologic response after treatment with direct-acting an

198 virus (HCV) and who do not have a sustained virologic response after treatment with regimens contain

199 or 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes i

200 mine the impacts of minority HIV variants on virologic response and clinical outcome.

201 Ninety-three percent achieved a sustained virologic response and DAA therapy was well tolerated.

202 Primary endpoints included sustained virologic response as defined as negative viral load at

203 imary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiv

204 n therapy and 100% have achieved a sustained virologic response at 12 weeks after completion of ledip

205 e proportion of patients achieving sustained virologic response at 12 weeks after the cessation of tr

206 The primary endpoint was sustained virologic response at 12 weeks after the end of treatmen

207 The primary end point was sustained virologic response at 12 weeks after therapy ended (SVR1

208 The primary endpoint was sustained virologic response at 12 weeks posttreatment (SVR12).

209 the percentage of patients with a sustained virologic response at 12 weeks posttreatment.

210 Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622/634) in t

211 The 2 patients who did not achieve sustained virologic response at 12 weeks were lost to follow-up ei

212 terval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%;

213 rval 93%-100%) of patients reached sustained virologic response at 12 weeks.

214 re to evaluate safety, the rate of sustained virologic response at post-treatment week 12 (SVR12), an

215 enters across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12).

216 as the percentage of patients with sustained virologic response at posttreatment week 12 (SVR12).

217 By intent-to-treat analysis, sustained virologic response at posttreatment week 12 was achieved

218 ary care had a noninferior rate of sustained virologic response at Week 12 (SVR12), compared to histo

219 dred percent of patients exhibited sustained virologic response at week 12 after the end of treatment

220 ease" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54

221 V at position 150, 71% achieved an sustained virologic response compared to 88% with A at position 15

222 Rates of sustained virologic response did not differ by receipt of treatmen

223 analysis on their association with sustained virologic response in a separate cohort of 411 patients

224 direct-acting agents with durable sustained virologic response in humans.

225 -acting agents to achieve complete sustained virologic response in humans.

226 2 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic

227 The overall sustained virologic response rate 12 weeks after the end of treatm

228 The sustained virologic response rate was 98% (102 of 104 patients; 95

229 antiviral regimens that offer high sustained virologic response rates even in the setting of immunosu

230 utcomes for coinfected patients as sustained virologic response rates now exceed 95% and fibrosis-rel

231 started treatment, and 9 achieved sustained virologic response thus far.

232 death was reduced in patients with sustained virologic response to DAA therapy (hazard ratio, 0.29; 9

233 This association differed by sustained virologic response to DAA therapy; risk of death was red

234 and in patients with vs without a sustained virologic response to therapy.

235 In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-velpatasvir-v

236 A sustained virologic response was associated with a lower risk of i

237 Sustained virologic response was high in nonadherent (89%) and adh

238 tistically significant decrease in sustained virologic response with DAA therapy.

239 Ten patients (66%) exhibited a rapid virologic response within 4 weeks (HCV GT1a, n = 4; HCV

240 The other 5 patients exhibited a virologic response within 8 (HCV GT 1b, n = 4) or 12 wee

241 risk for disease progression after sustained virologic response, the optimal approach to current DAA

242 on have demonstrated high rates of sustained virologic response, virologic failure may still occur, p

243 therapy for HCV despite achieving sustained virologic response.

244 ining this variant reduces odds of sustained virologic response.

245 C risk over time after DAA-induced sustained virologic response.

246 sk group for HCC after DAA-induced sustained virologic response.

247 nts; three of these patients had a sustained virologic response.

248 treatment initiation date and duration, and virologic response.

249 course, and 61 (50%) have achieved sustained virologic response.

250 All patients achieved sustained virologic response.

251 atients treated, 30 (97%) achieved sustained virologic response.

252 ring treatment and after achieving sustained virologic response.

253 patients that ultimately attain a sustained virologic response.

254 sepsis 4 months after achieving a sustained virologic response.

255 All 30 recipients achieved a sustained virologic response.

256 n HCV patients who did not achieve sustained virologic responses (SVRs) after treatment with direct-a

257 regimen and patients who achieved sustained virologic responses had the lowest risk for CVD events.

258 clonal B cells of MC patients with sustained virologic responses to direct-acting antivirals (DAAs),

259 glycoGag protein of MLV, suggesting that its virologic role is Nef specific.

260 FTA cards facilitate the transport of virologic samples at ambient temperature as noninfectiou

261 study, we characterized the immunologic and virologic status of BM-derived CD4(+) T cells in rhesus

262 Detailed virologic studies, including virus isolation and compreh

263 Our primary outcome was 96-week virologic success, defined as a sustained viral load <10

264 Administration of UB-421 maintained virologic suppression (<20 copies per milliliter) in all

265 ly in sensitivity analyses, included 48-week virologic suppression (88%-93%), subsequent virologic fa

266 UB-421 maintained virologic suppression (during the 8 to 16 weeks of study

267 ral blood of children who achieved sustained virologic suppression (SVS) for >=5 years.

268 Sustained virologic suppression (undetectable serum HBV DNA) witho

269 this is an immediate or long-term effect of virologic suppression (VS) in perinatal infection is unk

270 tting, as it improves retention in care with virologic suppression among patients with early clinical

271 t Pace of detection, linkage, retention, and virologic suppression and (2) NHAS investments in expand

272 of achieving intermediate outcomes, such as virologic suppression and hepatitis B e-antigen (HBeAg)

273 e show that HIV/CMV co-infected persons with virologic suppression and recovered CD4(+) T cells compa

274 nd placebo participants had similar times to virologic suppression and risks of virologic failure.

275 Rates of virologic suppression are lower in the total cohort amon

276 Virologic suppression at 18 months was similar between d

277 6 US and Canadian clinical cohorts, PWH with virologic suppression for >=1 year in 2005-2015 were fol

278 resistance (HIVDR) is a barrier to sustained virologic suppression in low- and middle-income countrie

279 TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and i

280 Virologic suppression of HIV-1 by ART during AHI impedes

281 numbers needed to treat ranged from 2.6 for virologic suppression to 17 for HBeAg seroconversion.

282 T during early HIV infection with subsequent virologic suppression up to 58 months.

283 We generated two more examples of virologic suppression using AAV delivery of a cocktail o

284 The 48-week virologic suppression varied (40%-92%) depending on TDR.

285 DTG/3TC was noninferior in maintaining virologic suppression vs a TAF-based regimen at week 48,

286 Despite lower exposure, virologic suppression was maintained and no perinatal tr

287 n human CD4+ T cells, could induce sustained virologic suppression without induction of resistance in

288 The aOR of virologic suppression, after adjusting for age, gender,

289 antiretroviral therapy (ART), 88.7% had HIV virologic suppression, and 80.8% had comorbidities.

290 ng and ART initiation improves retention and virologic suppression.

291 with more-extensive resistance, most achieve virologic suppression.

292 Recurrent HSIL was high despite virologic suppression.

293 We used US virologic surveillance and US Influenza Vaccine Effectiv

294 Here, using ILI records and virologic surveillance data, we show that ILI signal can

295 ion of influenza viruses was described using virologic surveillance data.

296 ey can be a useful tool for the expansion of virologic surveillance in countries where the reverse co

297 FTA cards have limited utility for virologic surveillance of sporadic cases of measles; how

298 control group met the primary outcome of HIV virologic testing performed before 8 weeks after birth (

299 Sociodemographic, clinical, and virologic variables were assessed as correlates of viral

300 receiving a TAF-based regimen met confirmed virologic withdrawal criteria, with no emergent resistan